IBKS No3 SPAC (225430) fair value: what the stock is really worth
As of Sep 14, 2026: fair value of IBKS No3 SPAC KRW 1,396, price KRW 698, upside +100.0%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch IBKS No3 SPAC for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range 525.00 KRW – 15,350 KRW · fair‑value band 1,042 KRW – 2,084 KRW · the 698.00 KRW price screens below the 1,396 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.
Follow IBKS No3 SPAC in your weekly email
Every Wednesday you see whether IBKS No3 SPAC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
KMPHARMACEUTICAL Co.,Ltd. engages in the manufacture, wholesale, and retail of oral care, beauty care, and other daily necessities in South Korea and internationally. The company offers toothpastes, toothbrushes, cosmetics, masks, hand cream, toothbrush and toothpaste, kids toothbrush, and baby finger toothbrush sets.
Show more
KMPHARMACEUTICAL Co.,Ltd. engages in the manufacture, wholesale, and retail of oral care, beauty care, and other daily necessities in South Korea and internationally. The company offers toothpastes, toothbrushes, cosmetics, masks, hand cream, toothbrush and toothpaste, kids toothbrush, and baby finger toothbrush sets. It also provides children's safety gargles, baby and light wipes, wet wipes, and steam eye masks; shampoos, body washes, sun creams, moisture creams, wrinkle functional cosmetics, and hair dyes; and dehumidifiers and hand sanitizers. The company was founded in 2001 and is headquartered in Pyeongtaek-si, South Korea.
Stock analysis
IBKS No3 SPAC (225430) currently trades at 698.00 KRW, while our model-based Fair Value estimate is 1,396 KRW, implying the stock looks roughly 50.0% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 1,042 KRW (bear) to 2,084 KRW (bull), the price of 698.00 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Financial Services sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
IBKS No3 SPAC reported revenue of 16.0B KRW in FY2025 versus 22.7B KRW in FY2021, a compound −8.4%/yr. Reported net income was −4.0B KRW in FY2025.
Key figures
Market cap 7.9B KRW (≈ $5.8M) · P/S ratio 0.48 · Net margin −24.8% · Return on equity −13.4% · Return on assets (EBIT) −3.2% · Operating margin −18.7% · Revenue (TTM) 16.4B KRW · Revenue growth (YoY) +9.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 87% below its 52-week high and 33% above its 52-week low.
For context, the median of 10 Financial Services peers we cover trades at −4% fair-value upside, at 100%, 225430 screens cheaper than that median.
Fair Value models
Bear 1,042 KRWFair Value 1,396 KRWBull 2,084 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+10.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.1%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.1% (2020) → −18.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Asset Management · 657 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is IBKS No3 SPAC (225430) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 1,396 KRW versus the last price from Sep 14, 2026 of 698.00 KRW, about +100% upside (undervalued).
What is the fair value of 225430?
Our model-based fair value for IBKS No3 SPAC is 1,396 KRW (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 14, 2026): 698.00 KRW.
What is the quality score of 225430?
IBKS No3 SPAC has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for IBKS No3 SPAC (225430)?
Our model-based price target is the fair value of 1,396 KRW (as of Sep 23, 2026) from 1 valuation models. Cautious scenario 1,042 KRW, optimistic scenario 2,084 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the IBKS No3 SPAC stock forecast for 2026?
Our models put fair value at 1,396 KRW, about +100% upside versus the last price from Sep 14, 2026 of 698.00 KRW (undervalued). Cautious scenario 1,042 KRW, optimistic scenario 2,084 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of IBKS No3 SPAC (225430)?
IBKS No3 SPAC reported trailing-twelve-month revenue of about 16.4B KRW (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of IBKS No3 SPAC (225430)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For IBKS No3 SPAC it is 1,396 KRW per share (as of Sep 23, 2026), against a price of 698.00 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is IBKS No3 SPAC stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 225430 trades below its calculated fair value: price 698.00 KRW, fair value 1,396 KRW, a gap of about +100% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 225430?
No. The price is what the market pays today (698.00 KRW); the fair value is what the company's own numbers justify (1,396 KRW). For IBKS No3 SPAC the two are 698.00 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is IBKS No3 SPAC worth?
The market values IBKS No3 SPAC at about 7.9B KRW (market capitalisation, as of Sep 23, 2026). Per share that is 698.00 KRW; our models calculate a fair value of 1,396 KRW per share.
What do the bullish and bearish scenarios say about 225430?
Our models span a range for IBKS No3 SPAC: cautious scenario 1,042 KRW, base 1,396 KRW, optimistic 2,084 KRW per share (as of Sep 23, 2026, price 698.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of IBKS No3 SPAC (225430)?
Balance-sheet figures for IBKS No3 SPAC (as of Sep 23, 2026): return on equity −13.4%, debt of 0.22 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 225430 from its 52-week high?
IBKS No3 SPAC trades at 698.00 KRW, about 87% below its 52-week high of 5,270 KRW and 33% above the low of 525.00 KRW (as of Sep 14, 2026). Distance from the high says nothing about value: that is what the fair value of 1,396 KRW is for.
Which stocks are comparable to IBKS No3 SPAC?
From the same area (Financial Services) we also value Blackstone Inc, Brookfield Corporation, KKR & Co, Apollo Global Management, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is IBKS No3 SPAC stock attractive at the current price?
The data as of Sep 23, 2026: price 698.00 KRW, calculated fair value 1,396 KRW (+100%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 225430 calculated?
We run IBKS No3 SPAC through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,396 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. IBKS No3 SPAC currently trades 100 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of IBKS No3 SPAC (225430)?
The latest price we hold is from Sep 14, 2026 and stands at 698.00 KRW. Our model-based fair value is 1,396 KRW, about +100% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with IBKS No3 SPAC right now?
The price is below even our cautious bear case (1,042 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (46/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (1,042 KRW to 2,084 KRW) leaves room in how you read the outcome.
Key figures of IBKS No3 SPAC
How large is the market capitalisation of IBKS No3 SPAC (225430)?
The market capitalisation of IBKS No3 SPAC is 7.9B KRW (≈ $5.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of IBKS No3 SPAC (225430)?
The price-to-sales ratio of IBKS No3 SPAC is 0.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of IBKS No3 SPAC (225430)?
The net margin of IBKS No3 SPAC is −24.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of IBKS No3 SPAC (225430)?
The return on equity (ROE) of IBKS No3 SPAC is −13.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of IBKS No3 SPAC (225430)?
On an EBIT basis the return on assets of IBKS No3 SPAC is −3.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of IBKS No3 SPAC (225430)?
The operating margin of IBKS No3 SPAC is −18.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at IBKS No3 SPAC (225430)?
Revenue at IBKS No3 SPAC is growing +9.5% versus a year earlier (3y avg +0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does IBKS No3 SPAC (225430) generate?
The free cash flow of IBKS No3 SPAC is −2.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does IBKS No3 SPAC (225430) carry?
The net debt of IBKS No3 SPAC is 15.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch IBKS No3 SPAC in the live analysis
One click puts IBKS No3 SPAC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
